Immune thrombocytopenia and thrombosis mortality predictors following SARS-CoV-2 vaccine
1. Low baseline platelet count and intracranial hemorrhage were shown to be prognostic mortality markers due to vaccine-induced immune thrombocytopenia ...
Tag: ChAdOx1 nCoV-19 vaccine
Third dose of ChAdOx1 nCoV-19 vaccine and prolonged second dose-intervals are both associated with increased antibody titers
1. An interval of 44-45 weeks between the first and second dose resulted in a four-fold increase in median antibody ...
Single dose mass vaccination against COVID-19 is linked with reductions in hospital admissions
1. The initial doses of the Pfizer and AstraZeneca vaccines were 91% and 88% efficacious in reducing COVID-19 hospitalizations one ...
#VisualAbstract: ChAdOx1 nCov-19 AstraZeneca COVID-19 vaccine not effective against B.1.351 variant
1. The ChAdOx1 nCov-19 (AstraZeneca) vaccine was not effective for the prevention of mild-to-moderate COVID-19 infection caused by the B.1.351 ...
ChAdOx1 nCov-19 AstraZeneca COVID-19 vaccine not effective against B.1.351 variant
1. The ChAdOx1 nCov-19 (AstraZeneca) vaccine was not effective for the prevention of mild-to-moderate COVID-19 infection caused by the B.1.351 ...
AstraZeneca coronavirus vaccine rarely causes immune thrombotic thrombocytopenia
1. ChAdOx1 nCov-19 vaccine has been linked to immune thrombotic thrombocytopenia in patients after vaccination resembling autoimmune heparin-induced thrombocytopenia. 2. ...
ChAdOx1 nCoV-19 (AstraZeneca) vaccine is effective against the SARS-CoV-2 B.1.1.7 variant
1. The AstraZeneca vaccine was 70.4% effective against the B.1.1.7 lineage, compared to 81.5% effective against non-B.1.1.7 lineages. 2. The ...
#VisualAbstract: ChAdOx1-nCoV-19 vaccine maintains efficacy despite a longer prime-boost interval
1. Overall vaccine efficacy at least 14-days after the second dose was 66.7%. 2. After the initial 21-day exclusion period, there ...
ChAdOx1-nCoV-19 vaccine maintains efficacy despite a longer prime-boost interval
1. Overall vaccine efficacy at least 14-days after the second dose was 66.7%. 2. After the initial 21-day exclusion period, ...
License Our Award-Winning Physician-Written Medical News and Visual Abstracts
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
